BPC-157, TB-500, & GHK-Cu Glow Stack

Third-party verified by MZ Biolabs (Tucson, AZ), a US DEA Schedule III licensed facility (License: RP0584676). Every batch undergoes rigorous HPLC purity analysis and Mass Spectrometry identity confirmation under Good Laboratory Practice (GLP) standards to ensure 99%+ purity and research reproducibility.

BPC-157

• Date: 07/03/25
• Purity Level: 99.85%

TB-500

• Date: 03/27/25
• Purity Level: 99.42%

GHK-Cu

• Date: 06/03/2025
• Purity Level: 99.99%

View all COAs at the bottom of this tab.

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in gastric juice.

In experimental models, BPC-157 has been studied for its role in:

• Cellular migration and tissue repair signaling
• Regulation of nitric oxide pathways
• Angiogenesis and vascular growth factors
• Gastrointestinal mucosal protection

Preclinical research suggests BPC-157 may influence growth factor signaling and nitric oxide synthase activity, which are both associated with tissue repair processes.

TB-500

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide involved in cellular regeneration.

Research models have examined TB-500 for its ability to:

• Promote actin polymerization and cell migration
• Support angiogenesis and tissue regeneration
• Influence inflammatory signaling pathways
• Assist extracellular matrix remodeling

These mechanisms are thought to help regulate structural cell movement during tissue repair processes.

GHK-Cu

GHK-Cu (Copper Tripeptide-1) is a naturally occurring peptide complex found in plasma and saliva that binds copper ions.

It has been studied for its role in:

• Collagen synthesis and skin remodeling
• Antioxidant enzyme activation
• Gene expression involved in tissue repair
• Extracellular matrix remodeling

Laboratory research indicates GHK-Cu can influence thousands of genes involved in regeneration and cellular signaling pathways.

BPC-157 Peptide

CAS Number: 137525-51-0

Formula: C₆₂H₉₈N₁₆O₂₂

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Molar Mass: 1,419.5 g/mol

Half-life: 4 hours

Class: Polypeptide

Storage: Keep refrigerated upon reconstitution.

• Lyophilized sample in a sterile glass vial.
• Minimum 98% pure.
• 5 mg BPC-157 per vial.
• Diluent and laboratory supplies are not included.

TB-500 Peptide

CAS Number: 77591-33-4

Formula: C₂₁₂H₃₅₀N₅₆O₇₈S

Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH

Molecular Weight: 4963.49 g/mol

Class: Polypeptide

Storage: Keep refrigerated upon reconstitution.

• Lyophilized sample in a sterile glass vial.
• Minimum 99% pure.
• 5 mg TB-500 per vial.
• Diluent and laboratory supplies are not included.

GHK-Cu

CAS Number: 89030-95-5

Formula: C₁₄H₂₂CuN₆O₄

Sequence: (GLY-HIS-LYS)-Cu-HAc

Molar Mass: 340.38 g/mol

Class: Tripeptide

• Note: The Product is purple due to the presence of Cu (copper)

Storage: Keep refrigerated upon reconstitution.

• Lyophilized sample in a sterile glass vial.
• Minimum 98% pure.
• 50 mg GHK-Cu peptide per vial.
• Diluent and laboratory supplies are not included.

SKU: 68

Abuse Warning

Disclaimer: Our products are for in vitro laboratory research purposes only by licensed professionals and are not approved by the FDA for bodily introduction into humans or animals.

Scientific References:

1. Drmic D, Samara M, Vidovic T, Malekinusic D, Antunovic M, Vrdoljak B, Ruzman J, Milkovic Perisa M, Horvat Pavlov K, Jeyakumar J, Seiwerth S, Sikiric P. Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC-157, L-NAME and L-arginine. World J Gastroenterol. 2018 Dec 28;24(48):5462-5476. doi: 10.3748/wjg.v24.i48.5462. PMID: 30622376; PMCID: PMC6319139.

2. Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015 Apr 30;9:2485-99. doi: 10.2147/DDDT.S82030. PMID: 25995620; PMCID: PMC4425239.

3. Amic F, Drmic D, Bilic Z, Krezic I, Zizek H, Peklic M, Klicek R, Pajtak A, Amic E, Vidovic T, Rakic M, Milkovic Perisa M, Horvat Pavlov K, Kokot A, Tvrdeic A, Boban Blagaic A, Zovak M, Seiwerth S, Sikiric P. Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC-157, L-NAME and L-arginine. World J Gastroenterol. 2018 Dec 21;24(47):5366-5378. doi: 10.3748/wjg.v24.i47.5366. PMID: 30598581; PMCID: PMC6305534.

4. Duzel A, Vlainic J, Antunovic M, Malekinusic D, Vrdoljak B, Samara M, Gojkovic S, Krezic I, Vidovic T, Bilic Z, Knezevic M, Sever M, Lojo N, Kokot A, Kolovrat M, Drmic D, Vukojevic J, Kralj T, Kasnik K, Siroglavic M, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC-157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. World J Gastroenterol. 2017 Dec 28;23(48):8465-8488. doi: 10.3748/wjg.v23.i48.8465. PMID: 29358856; PMCID: PMC5752708.

5. Vukojević J, Siroglavić M, Kašnik K, Kralj T, Stanćić D, Kokot A, Kolarić D, Drmić D, Sever AZ, Barišić I, Šuran J, Bojić D, Patrlj MH, Sjekavica I, Pavlov KH, Vidović T, Vlainić J, Stupnišek M, Seiwerth S, Sikirić P. Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC-157. Vascul Pharmacol. 2018 Jul;106:54-66. doi: 10.1016/j.vph.2018.02.010. Epub 2018 Mar 3. PMID: 29510201.

6. Drmic D, Kolenc D, Ilic S, Bauk L, Sever M, Zenko Sever A, Luetic K, Suran J, Seiwerth S, Sikiric P. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC-157 or L-arginine, aggravation by L-NAME. World J Gastroenterol. 2017 Aug 7;23(29):5304-5312. doi: 10.3748/wjg.v23.i29.5304. PMID: 28839430; PMCID: PMC5550779.

7. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Therapeutic potential of pro-angiogenic BPC-157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017 Mar;95(3):323-333. doi: 10.1007/s00109-016-1488-y. Epub 2016 Nov 15. PMID: 27847966.

8. Grabarevic Z, Tisljar M, Artukovic B, Bratulic M, Dzaja P, Seiwerth S, Sikiric P, Peric J, Geres D, Kos J. The influence of BPC-157 on nitric oxide agonist and antagonist-induced lesions in broiler chicks. J Physiol Paris. 1997 May-Oct;91(3-5):139-49. doi: 10.1016/s0928-4257(97)89478-8. PMID: 9403788.

9. Škrlec K, Ručman R, Jarc E, Sikirić P, Švajger U, Petan T, Perišić Nanut M, Štrukelj B, Berlec A. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Appl Microbiol Biotechnol. 2018 Dec;102(23):10103-10117. doi: 10.1007/s00253-018-9333-6. Epub 2018 Sep 6. PMID: 30191288.

10. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, Klicek R, Radic B, Keller N, Sipos K, Jakir A, Udovicic M, Tonkic A, Kokic N, Turkovic B, Mise S, Anic T. Stable gastric pentadecapeptide BPC-157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006 Dec;14(5-6):214-21. doi: 10.1007/s10787-006-1531-7. PMID: 17186181.

11. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vrcic H, Sebecic B. Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. doi: 10.2174/138161211796196954. PMID: 21548867.

12. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC-157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676.

13. Unveiling the Wolverine Peptide: Exploring Its Potential for Healing and Regeneration. Peptide Information (2023)

14.  Tokura Y, Nakayama Y, Fukada S, Nara N, Yamamoto H, Matsuda R, Hara T. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011 Jan;149(1):43-8. doi: 10.1093/jb/mvq115. Epub 2010 Sep 29. PMID: 20880960.

15. Vasilopoulou E, Kolatsi-Joannou M, Lindenmeyer MT, White KE, Robson MG, Cohen CD, Sebire NJ, Riley PR, Winyard PJ, Long DA. Loss of endogenous thymosin β₄ accelerates glomerular disease. Kidney Int. 2016 Nov;90(5):1056-1070. doi: 10.1016/j.kint.2016.06.032. Epub 2016 Aug 26. PMID: 27575556; PMCID: PMC5073078.

16. Brady RD, Grills BL, Schuijers JA, Ward AR, Tonkin BA, Walsh NC, McDonald SJ. Thymosin β4 administration enhances fracture healing in mice. J Orthop Res. 2014 Oct;32(10):1277-82. doi: 10.1002/jor.22686. Epub 2014 Jul 8. PMID: 25042765.

17. Cheng P, Kuang F, Zhang H, Ju G, Wang J. Beneficial effects of thymosin β4 on spinal cord injury in the rat. Neuropharmacology. 2014 Oct;85:408-16. doi: 10.1016/j.neuropharm.2014.06.004. Epub 2014 Jun 14. PMID: 24937047.

18. Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M. Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012 Oct;1270:51-8. Doi: 10.1111/j.1749-6632.2012.06683.x. PMID: 23050817; PMCID: PMC3547647.

19. Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-75. doi: 10.1016/bs.vh.2016.04.005. Epub 2016 May 24. PMID: 27450738.

20. https://clinicaltrials.gov/show/NCT00598871

21. Exploring the Potential of Thymosin Peptide in Immune Function and Healing. Peptide Information (2023).

22. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β4. Expert Opin Biol Ther. 2015;15 Suppl 1:S139-45. doi: 10.1517/14712598.2015.1011617. Epub 2015 Jun 22. PMID: 26096726.

23. Wang, X., Liu, B., Xu, Q., Sun, H., Shi, M., Wang, D., … & Feng, B. (2017). GHK‐Cu‐liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound repair and regeneration, 25(2), 270-278.

24. Zhao, R., Chen, Y., Ma, Y., Zou, C., Zhang, J., & Chen, Z. (2022). Innovation and transformation of chronic airway diseases. Frontiers in Molecular Biosciences, 9, 1089813.

25. Lau, S. J., & Sarkar, B. (1981). The interaction of copper (II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochemical Journal, 199(3), 649-656.

26. Pickart L, et al. The human tri-peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity. 2012; 2012: 324832. Doi: 10.1155/2012/324832.